pioglitazone has been researched along with Polycystic Ovarian Syndrome in 90 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the number of follicles was higher in the pioglitazone group, our study showed no differences in ovary stimulation and pregnancy rate." | 9.41 | Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome. ( Amirian, M; Jafarian, F; Mirteimouri, M; Nikdoust, S; Niroumand, S; Payrovnaziri, A; Salehi, M; Shariat Moghani, S, 2021) |
| "This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress." | 9.34 | Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. ( Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H, 2020) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 9.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "To examine the efficacy of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone among women with polycystic ovary syndrome (PCOS) resistant to clomifene citrate." | 9.22 | A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome. ( Abdel Moety, G; Al Mohammady, M; El-khayat, W; Hamed, D, 2016) |
| " PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin." | 9.19 | Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 9.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight." | 9.16 | Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. ( Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A, 2012) |
| "To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS)." | 9.16 | Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. ( Berge, RK; Bjørndal, B; Bohov, P; Gaster, M; Glintborg, D; Nygård, O; Seifert, R; Svardal, A; Vigerust, NF, 2012) |
| "We designed a study, involving 52 patients of 19-36 years of age, to test the pioglitazone in women with polycystic ovary syndrome." | 9.16 | Pioglitazone reduces central obesity in polycystic ovary syndrome women. ( Asadipooya, K; Kalantar-Hormozi, M; Nabipour, I, 2012) |
| "In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance." | 9.15 | Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. ( Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A, 2011) |
| "To study the clinical, metabolic and adverse effects of pioglitazone over a period of 6 months in obese adolescent and young adults with polycystic ovary syndrome." | 9.14 | Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. ( Jacob, JJ; Narsing Rao, L; Paul, TV; Rajarathinam, S; Seshadri, MS; Thomas, N, 2009) |
| "To investigate the effects of pioglitazone on ovarian stimulation, in vitro fertilization (IVF) outcome, and intraovarian stromal blood flow in patients with polycystic ovary syndrome (PCOS)." | 9.14 | Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. ( Chae, HD; Jeon, GH; Kang, BM; Kim, CH; Kim, SH; Kim, SR, 2010) |
| "Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone treatment." | 9.14 | Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment. ( Aigner, E; Bachofner, N; Datz, C; De Geyter, C; Hohla, F; Klein, K; Patsch, W, 2009) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 9.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "Insulin sensitivity, GH, adiponectin, and IGF-I significantly increased during pioglitazone treatment, whereas alloTHF/THF levels significantly decreased." | 9.14 | A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. ( Andersen, M; Bennett, P; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Hermann, AP; Jensen, LT, 2009) |
| "Our objective was to investigate the effect of pioglitazone on bone mineral density (BMD) and bone turnover markers in polycystic ovary syndrome (PCOS)." | 9.13 | Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. ( Andersen, M; Glintborg, D; Hagen, C; Heickendorff, L; Hermann, AP, 2008) |
| " Following pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3." | 9.13 | Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Handberg, A; Henriksen, JE; Højlund, K, 2008) |
| "To investigate the efficacy of pioglitazone on fecundity in infertile patients with polycystic ovary syndrome (PCOS) who are resistant to conventional ovulation induction such as clomiphene, dexamethasone, or metformin." | 9.13 | Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. ( Goto, T; Ohyama, N; Ota, H; Yoshioka, T, 2008) |
| " The ability of pioglitazone to enhance insulin sensitivity, in part, involves improved insulin action on GS activity and dephosphorylation at NH2-terminal sites." | 9.13 | Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. ( Andersen, NR; Beck-Nielsen, H; Glintborg, D; Hansen, BF; Højlund, K; Wojtaszewski, JF, 2008) |
| " In the present study we evaluated total and HMW adiponectin in polycystic ovary syndrome (PCOS) patients and controls and examined possible mechanisms for increased insulin sensitivity during pioglitazone treatment." | 9.13 | Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. ( Andersen, KK; Andersen, M; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Henriksen, JE; Hermann, AP; Højlund, K, 2008) |
| "To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, beta-cell function, LH secretion, and glucose metabolism." | 9.12 | Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Hagen, C; Henriksen, JE; Hermann, AP; Veldhuis, JD, 2006) |
| " Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion." | 9.11 | Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. ( Andersen, M; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Hermann, AP; Støving, RK; Veldhuis, JD, 2005) |
| "Pioglitazone treatment significantly reduced the insulin response to OGTT and improved the insulin sensitivity indices (P < 0." | 9.11 | Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. ( Apa, R; Costantini, B; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D; Suriano, R, 2004) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion." | 9.10 | Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 8.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 8.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "Metformin is an effective treatment for anovulation in women with PCOS." | 8.82 | Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "To evaluate the effects of pioglitazone on menstruation and the metabolic parameters of non-obese women of reproductive age with polycystic ovary syndrome (PCOS) and compare the effects among different subgroups of PCOS patients with different clinical presentations." | 7.74 | Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. ( Choi, D; Koo, YA; Shin, SY; Yoon, BK, 2007) |
| "In an observational study of 13 women with polycystic ovary syndrome (PCOS) not optimally responsive to metformin diet, we assessed the efficacy and safety of addition of pioglitazone." | 7.72 | Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. ( Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P, 2003) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 6.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Pioglitazone treatment significantly improved insulin sensitivity without affecting testosterone, body composition, MCP-1, MIP-1alpha and MIF levels." | 6.74 | Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. ( Andersen, M; Bruun, JM; Glintborg, D; Richelsen, B, 2009) |
| "Hyperinsulinemia is involved in the adrenal hyper-responsiveness to ACTH." | 6.73 | Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. ( Costantini, B; Cristello, F; Draisci, G; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D, 2007) |
| "Treatment with pioglitazone was also associated with higher ovulation rates (P < 0." | 6.71 | Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. ( Brettenthaler, N; De Geyter, C; Huber, PR; Keller, U, 2004) |
| "With pioglitazone treatment, E(2) responses to r-hFSH remained unchanged during low-dose insulin infusion, whereas a highly significant (P < 0." | 6.71 | Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. ( Chang, RJ; Coffler, MS; Dahan, MH; Malcom, PJ; Patel, K; Yoo, RY, 2003) |
| "Metformin was used as a positive control." | 5.91 | Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. ( He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H, 2023) |
| "Pioglitazone treatment did not influence body weight or ovarian weight in either group." | 5.48 | Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. ( Baba, T; Endo, T; Honnma, H; Ikeda, K; Kiya, T; Kuno, Y; Morishita, M; Saito, T, 2018) |
| "Although the number of follicles was higher in the pioglitazone group, our study showed no differences in ovary stimulation and pregnancy rate." | 5.41 | Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome. ( Amirian, M; Jafarian, F; Mirteimouri, M; Nikdoust, S; Niroumand, S; Payrovnaziri, A; Salehi, M; Shariat Moghani, S, 2021) |
| "A total of 27 RCTs with 12 interventions were included, and all therapies tended to increase clinical pregnancy, especially pioglitazone (PIO) (log OR 3." | 5.41 | The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. ( Li, J; Liu, Y; Ma, J; Peng, G; Tong, N; Wang, Y; Yan, Z, 2023) |
| "Treatment with pioglitazone improved insulin-stimulated glucose metabolism and plasma adiponectin, and reduced fasting serum insulin (all P<0." | 5.35 | Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. ( Beck-Nielsen, H; Glintborg, D; Højlund, K; Jensen, T; Knudsen, S; Kruse, TA; Skov, V; Tan, Q, 2008) |
| "This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress." | 5.34 | Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. ( Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H, 2020) |
| " In patients with polycystic ovary syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is associated with an increase in muscle ApoJ and LRP2 expression." | 5.34 | Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. ( Aroda, V; Ciaraldi, TP; Dagon, Y; Henry, RR; Heo, JI; Hong, SH; Huang, H; Hwang, WM; Kang, MC; Kim, MS; Kim, SS; Kim, YB; Lee, SH; Lima, IS; Park, KS; Pereira de Moura, L; Seo, JA; Uner, A; Vijyakumar, A; Willnow, TE; Yang, WM, 2020) |
| "The reason why hyperinsulinemia produces hyperandrogenism and whether insulin action on the pituitary alters gonadotropin liberation remain unknown." | 5.33 | Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. ( Garmes, HM; Tambascia, MA; Zantut-Wittmann, DE, 2005) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 5.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| " A significant reduction in homoeostatic model assessment of insulin resistance (HOMA-IR) was seen with exenatide versus metformin (MD: -0." | 5.22 | Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. ( Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N, 2022) |
| "To examine the efficacy of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone among women with polycystic ovary syndrome (PCOS) resistant to clomifene citrate." | 5.22 | A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome. ( Abdel Moety, G; Al Mohammady, M; El-khayat, W; Hamed, D, 2016) |
| " PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin." | 5.19 | Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 5.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS)." | 5.16 | Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. ( Berge, RK; Bjørndal, B; Bohov, P; Gaster, M; Glintborg, D; Nygård, O; Seifert, R; Svardal, A; Vigerust, NF, 2012) |
| "We designed a study, involving 52 patients of 19-36 years of age, to test the pioglitazone in women with polycystic ovary syndrome." | 5.16 | Pioglitazone reduces central obesity in polycystic ovary syndrome women. ( Asadipooya, K; Kalantar-Hormozi, M; Nabipour, I, 2012) |
| "these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight." | 5.16 | Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. ( Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A, 2012) |
| "In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance." | 5.15 | Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. ( Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A, 2011) |
| "To study the clinical, metabolic and adverse effects of pioglitazone over a period of 6 months in obese adolescent and young adults with polycystic ovary syndrome." | 5.14 | Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. ( Jacob, JJ; Narsing Rao, L; Paul, TV; Rajarathinam, S; Seshadri, MS; Thomas, N, 2009) |
| "To investigate the effects of pioglitazone on ovarian stimulation, in vitro fertilization (IVF) outcome, and intraovarian stromal blood flow in patients with polycystic ovary syndrome (PCOS)." | 5.14 | Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. ( Chae, HD; Jeon, GH; Kang, BM; Kim, CH; Kim, SH; Kim, SR, 2010) |
| "Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone treatment." | 5.14 | Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment. ( Aigner, E; Bachofner, N; Datz, C; De Geyter, C; Hohla, F; Klein, K; Patsch, W, 2009) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 5.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "Insulin sensitivity, GH, adiponectin, and IGF-I significantly increased during pioglitazone treatment, whereas alloTHF/THF levels significantly decreased." | 5.14 | A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. ( Andersen, M; Bennett, P; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Hermann, AP; Jensen, LT, 2009) |
| " In the present study we evaluated total and HMW adiponectin in polycystic ovary syndrome (PCOS) patients and controls and examined possible mechanisms for increased insulin sensitivity during pioglitazone treatment." | 5.13 | Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. ( Andersen, KK; Andersen, M; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Henriksen, JE; Hermann, AP; Højlund, K, 2008) |
| " The ability of pioglitazone to enhance insulin sensitivity, in part, involves improved insulin action on GS activity and dephosphorylation at NH2-terminal sites." | 5.13 | Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. ( Andersen, NR; Beck-Nielsen, H; Glintborg, D; Hansen, BF; Højlund, K; Wojtaszewski, JF, 2008) |
| "To investigate the efficacy of pioglitazone on fecundity in infertile patients with polycystic ovary syndrome (PCOS) who are resistant to conventional ovulation induction such as clomiphene, dexamethasone, or metformin." | 5.13 | Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. ( Goto, T; Ohyama, N; Ota, H; Yoshioka, T, 2008) |
| "Our objective was to investigate the effect of pioglitazone on bone mineral density (BMD) and bone turnover markers in polycystic ovary syndrome (PCOS)." | 5.13 | Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. ( Andersen, M; Glintborg, D; Hagen, C; Heickendorff, L; Hermann, AP, 2008) |
| " Following pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3." | 5.13 | Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Handberg, A; Henriksen, JE; Højlund, K, 2008) |
| "To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, beta-cell function, LH secretion, and glucose metabolism." | 5.12 | Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Hagen, C; Henriksen, JE; Hermann, AP; Veldhuis, JD, 2006) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "To investigate whether the long-term administration of metformin or pioglitazone to women with polycystic ovary syndrome (PCOS) could induce changes in their hypothalamic dopaminergic (DA) tone and to analyze whether these changes correlated with modifications in insulin resistance, we originally studied 57 obese hyperinsulinemic, non-diabetic, insulin resistant women with PCOS, but only 34 completed the study." | 5.11 | Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. ( Arteaga-Troncoso, G; Cardoza, L; Coutiño, B; Hidalgo, R; Ortega-González, C; Parra, A, 2005) |
| "Pioglitazone treatment significantly reduced the insulin response to OGTT and improved the insulin sensitivity indices (P < 0." | 5.11 | Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. ( Apa, R; Costantini, B; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D; Suriano, R, 2004) |
| " Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion." | 5.11 | Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. ( Andersen, M; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Hermann, AP; Støving, RK; Veldhuis, JD, 2005) |
| "To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion." | 5.10 | Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 4.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| ", pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production." | 4.93 | Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS. ( Indran, IR; Lee, BH; Yong, EL, 2016) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 4.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| " Key terms used were thiazolidinediones, troglitazone, rosiglitazone, pioglitazone, polycystic ovary syndrome, and PCOS." | 4.82 | Thiazolidinediones for treatment of polycystic ovary syndrome. ( Fugate, SE; Stout, DL, 2005) |
| "Metformin is an effective treatment for anovulation in women with PCOS." | 4.82 | Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "The combination of pioglitazone and α-lipoic acid has a significantly improving effect on BMI, body weight, oxidative stress levels, lipid metabolism, and menstrual status." | 4.31 | Beneficial effects of pioglitazone and α-lipoic acid in patients with polycystic ovaries syndrome. ( Hu, H; Liu, YY; Pei, Y; Sun, M; Wang, B; Wang, ZL; Zheng, J; Zhou, TT, 2023) |
| "To evaluate the effect of metformin and pioglitazone on leutinizing hormone and follicle stimulating hormone receptor mRNA expression, hyperandrogenism and insulin resistance in high fat diet induced and letrozole induced PCOS in rats." | 3.88 | Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. ( Patel, R; Shah, G, 2018) |
| "The combination of dimethylbiguanide and pioglitazone was more effective for the treatment of PCOS complicated with IR than simple pioglitazone; chronic inflammation occurrence was possibly one of reasons for insulin sensitivity reduction of patients with PCOS." | 3.80 | Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. ( Hu, L; Hu, MH; Shen, H; Tian, L; Wu, QF, 2014) |
| "To evaluate the effects of pioglitazone on menstruation and the metabolic parameters of non-obese women of reproductive age with polycystic ovary syndrome (PCOS) and compare the effects among different subgroups of PCOS patients with different clinical presentations." | 3.74 | Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. ( Choi, D; Koo, YA; Shin, SY; Yoon, BK, 2007) |
| "In an observational study of 13 women with polycystic ovary syndrome (PCOS) not optimally responsive to metformin diet, we assessed the efficacy and safety of addition of pioglitazone." | 3.72 | Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. ( Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P, 2003) |
| " Co-supplementation of high dosage VD with spironolactone or pioglitazone are more effective in reducing plasma leptin levels than metformin, and thus might prove to be better therapeutic strategies for women with PCOS." | 2.94 | Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study. ( Bhat, GA; Ganie, MA; Rashid, A; Shah, ZA; Shaheen, F; Shrivastava, M; Wani, IA, 2020) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 2.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Pioglitazone treatment significantly improved insulin sensitivity without affecting testosterone, body composition, MCP-1, MIP-1alpha and MIF levels." | 2.74 | Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. ( Andersen, M; Bruun, JM; Glintborg, D; Richelsen, B, 2009) |
| "Hyperinsulinemia is involved in the adrenal hyper-responsiveness to ACTH." | 2.73 | Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. ( Costantini, B; Cristello, F; Draisci, G; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D, 2007) |
| "Treatment with pioglitazone was also associated with higher ovulation rates (P < 0." | 2.71 | Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. ( Brettenthaler, N; De Geyter, C; Huber, PR; Keller, U, 2004) |
| "With pioglitazone treatment, E(2) responses to r-hFSH remained unchanged during low-dose insulin infusion, whereas a highly significant (P < 0." | 2.71 | Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. ( Chang, RJ; Coffler, MS; Dahan, MH; Malcom, PJ; Patel, K; Yoo, RY, 2003) |
| "Pioglitazone was used to treat patients of PCOS in many researches, but the treatment has not been recognized by public or recommended by all the guidelines." | 2.55 | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. ( Huang, Q; Wu, Y; Xu, Y, 2017) |
| " The secondary outcome measures include acne scores, prevalence of dysglycaemia, BMI, lipid profile, total testosterone level, and adverse events." | 2.52 | The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Flórez, ID; Neupane, B; Thabane, L, 2015) |
| "Metformin treatment was shown to improve these features, although conflicting results were also reported." | 2.46 | Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. ( Hatzitolios, AI; Katsiki, N, 2010) |
| "Type 2 diabetes is a disorder that has numerous components, including insulin resistance, an insulin secretory defect, and an increase in hepatic glucose production." | 2.41 | Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. ( Peters, AL, 2001) |
| "Metformin was used as a positive control." | 1.91 | Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. ( He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H, 2023) |
| "Polycystic ovary syndrome affects 7% of women of reproductive ages." | 1.62 | Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis. ( Dehghan, Z; Mirmotalebisohi, SA; Mohammadi-Yeganeh, S; Salehi, M; Sameni, M; Zali, H, 2021) |
| "Pioglitazone treatment did not influence body weight or ovarian weight in either group." | 1.48 | Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. ( Baba, T; Endo, T; Honnma, H; Ikeda, K; Kiya, T; Kuno, Y; Morishita, M; Saito, T, 2018) |
| "Treatment with pioglitazone improved insulin-stimulated glucose metabolism and plasma adiponectin, and reduced fasting serum insulin (all P<0." | 1.35 | Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. ( Beck-Nielsen, H; Glintborg, D; Højlund, K; Jensen, T; Knudsen, S; Kruse, TA; Skov, V; Tan, Q, 2008) |
| "The reason why hyperinsulinemia produces hyperandrogenism and whether insulin action on the pituitary alters gonadotropin liberation remain unknown." | 1.33 | Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. ( Garmes, HM; Tambascia, MA; Zantut-Wittmann, DE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (41.11) | 29.6817 |
| 2010's | 31 (34.44) | 24.3611 |
| 2020's | 22 (24.44) | 2.80 |
| Authors | Studies |
|---|---|
| Dehghan, Z | 1 |
| Mohammadi-Yeganeh, S | 1 |
| Sameni, M | 1 |
| Mirmotalebisohi, SA | 1 |
| Zali, H | 1 |
| Salehi, M | 2 |
| Abdalla, MA | 2 |
| Shah, N | 2 |
| Deshmukh, H | 2 |
| Sahebkar, A | 2 |
| Östlundh, L | 2 |
| Al-Rifai, RH | 2 |
| Atkin, SL | 5 |
| Sathyapalan, T | 3 |
| Hassan, S | 1 |
| Shah, M | 2 |
| Malik, MO | 2 |
| Ehtesham, E | 2 |
| Habib, SH | 1 |
| Rauf, B | 1 |
| Onal, T | 1 |
| Tulay, P | 1 |
| Vatansever, HS | 1 |
| Garcia-Beltran, C | 5 |
| Bassols, J | 3 |
| Carreras-Badosa, G | 1 |
| López Bermejo, A | 1 |
| Ibáñez, L | 12 |
| de Zegher, F | 11 |
| Zhao, H | 1 |
| Wang, D | 1 |
| Xing, C | 1 |
| Lv, B | 1 |
| Wang, X | 1 |
| He, B | 1 |
| Díaz, M | 7 |
| Peng, G | 1 |
| Yan, Z | 1 |
| Liu, Y | 1 |
| Li, J | 1 |
| Ma, J | 1 |
| Tong, N | 1 |
| Wang, Y | 1 |
| Zeng, H | 1 |
| Huang, Y | 1 |
| Liu, D | 1 |
| Xie, T | 1 |
| Chen, Z | 1 |
| Huang, Q | 3 |
| Zhou, X | 1 |
| Lai, X | 1 |
| Liu, J | 1 |
| Pei, Y | 1 |
| Liu, YY | 1 |
| Sun, M | 1 |
| Zheng, J | 1 |
| Zhou, TT | 1 |
| Wang, B | 1 |
| Hu, H | 1 |
| Wang, ZL | 1 |
| Malpique, R | 4 |
| Andersen, MS | 1 |
| Bas, F | 1 |
| Darendeliler, F | 1 |
| Dieris, B | 1 |
| Fanelli, F | 1 |
| Fröhlich-Reiterer, E | 1 |
| Gambineri, A | 1 |
| Glintborg, D | 13 |
| López-Bermejo, A | 8 |
| Mann, C | 1 |
| Marin, S | 1 |
| Obermayer-Pietsch, B | 1 |
| Ødegård, R | 1 |
| Ravn, P | 1 |
| Reinehr, T | 1 |
| Renzulli, M | 1 |
| Salvador, C | 1 |
| Singer, V | 1 |
| Vanky, E | 1 |
| Torres, JV | 1 |
| Yildiz, M | 1 |
| Ali, DE | 1 |
| Ali, A | 1 |
| Rehman, F | 1 |
| Badshah, H | 1 |
| Vitale, SG | 1 |
| Zeng, X | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Rashid, A | 1 |
| Ganie, MA | 1 |
| Wani, IA | 2 |
| Bhat, GA | 1 |
| Shaheen, F | 1 |
| Shrivastava, M | 1 |
| Shah, ZA | 1 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Villarroya, F | 2 |
| Seo, JA | 1 |
| Kang, MC | 1 |
| Yang, WM | 1 |
| Hwang, WM | 1 |
| Kim, SS | 1 |
| Hong, SH | 1 |
| Heo, JI | 1 |
| Vijyakumar, A | 1 |
| Pereira de Moura, L | 1 |
| Uner, A | 1 |
| Huang, H | 1 |
| Lee, SH | 1 |
| Lima, IS | 1 |
| Park, KS | 1 |
| Kim, MS | 1 |
| Dagon, Y | 1 |
| Willnow, TE | 1 |
| Aroda, V | 2 |
| Ciaraldi, TP | 3 |
| Henry, RR | 3 |
| Kim, YB | 1 |
| Guo, QJ | 1 |
| Shan, J | 1 |
| Xu, YF | 1 |
| Hu, YY | 1 |
| Huo, CL | 1 |
| Song, JY | 1 |
| Wang, CQ | 1 |
| Zhou, H | 1 |
| Yu, CQ | 1 |
| Carbonetto, B | 1 |
| González-Torres, P | 1 |
| Henares, D | 1 |
| Brotons, P | 1 |
| Muñoz-Almagro, C | 1 |
| Villarroya, J | 1 |
| Cairó, M | 1 |
| Amirian, M | 1 |
| Shariat Moghani, S | 1 |
| Jafarian, F | 1 |
| Mirteimouri, M | 1 |
| Nikdoust, S | 1 |
| Niroumand, S | 1 |
| Payrovnaziri, A | 1 |
| Jensterle, M | 1 |
| Goricar, K | 1 |
| Janez, A | 1 |
| Dawson, AJ | 1 |
| Kilpatrick, ES | 2 |
| Coady, AM | 2 |
| Elshewehy, AMM | 1 |
| Dakroury, Y | 1 |
| Ahmed, L | 1 |
| Del Río, L | 2 |
| Sebastiani, G | 1 |
| Pozo, ÓJ | 1 |
| Xu, Y | 1 |
| Wu, Y | 1 |
| Morley, LC | 1 |
| Tang, T | 1 |
| Yasmin, E | 1 |
| Norman, RJ | 2 |
| Balen, AH | 1 |
| Morishita, M | 1 |
| Endo, T | 2 |
| Baba, T | 1 |
| Kuno, Y | 1 |
| Ikeda, K | 1 |
| Kiya, T | 1 |
| Honnma, H | 1 |
| Saito, T | 1 |
| Patel, R | 1 |
| Shah, G | 1 |
| Uliassi, N | 1 |
| Sullivan, S | 1 |
| Damle, L | 1 |
| Gomez-Lobo, V | 1 |
| Sánchez-Infantes, D | 1 |
| Taxerås, SD | 1 |
| Mudaliar, SR | 1 |
| Kabiri, N | 1 |
| Tabandeh, MR | 1 |
| Tabatabaie, SR | 1 |
| Stabile, G | 1 |
| Borrielli, I | 1 |
| Artenisio, AC | 1 |
| Bruno, LM | 1 |
| Benvenga, S | 1 |
| Giunta, L | 1 |
| La Marca, A | 1 |
| Volpe, A | 1 |
| Pizzo, A | 1 |
| Hu, L | 1 |
| Shen, H | 1 |
| Wu, QF | 1 |
| Tian, L | 1 |
| Hu, MH | 1 |
| Al Khalifah, RA | 1 |
| Flórez, ID | 1 |
| Dennis, B | 1 |
| Neupane, B | 1 |
| Thabane, L | 1 |
| Bassilious, E | 1 |
| El-khayat, W | 1 |
| Abdel Moety, G | 1 |
| Al Mohammady, M | 1 |
| Hamed, D | 1 |
| Indran, IR | 1 |
| Lee, BH | 1 |
| Yong, EL | 1 |
| Højlund, K | 5 |
| Andersen, NR | 2 |
| Hansen, BF | 1 |
| Beck-Nielsen, H | 6 |
| Wojtaszewski, JF | 2 |
| Cho, LW | 2 |
| Keevil, BG | 1 |
| Skov, V | 2 |
| Knudsen, S | 1 |
| Tan, Q | 1 |
| Jensen, T | 1 |
| Kruse, TA | 1 |
| Aroda, VR | 1 |
| Burke, P | 1 |
| Mudaliar, S | 1 |
| Clopton, P | 1 |
| Phillips, S | 1 |
| Chang, RJ | 3 |
| Kawamura, S | 1 |
| Sakai, A | 1 |
| Maruta, M | 1 |
| Aigner, E | 1 |
| Bachofner, N | 1 |
| Klein, K | 1 |
| De Geyter, C | 2 |
| Hohla, F | 1 |
| Patsch, W | 1 |
| Datz, C | 1 |
| Andersen, M | 7 |
| Richelsen, B | 1 |
| Bruun, JM | 1 |
| Kim, CH | 1 |
| Jeon, GH | 1 |
| Kim, SR | 1 |
| Kim, SH | 1 |
| Chae, HD | 1 |
| Kang, BM | 1 |
| Narsing Rao, L | 1 |
| Jacob, JJ | 1 |
| Paul, TV | 1 |
| Rajarathinam, S | 1 |
| Thomas, N | 1 |
| Seshadri, MS | 1 |
| Enríquez, G | 1 |
| Naka, KK | 1 |
| Kalantaridou, SN | 1 |
| Kravariti, M | 1 |
| Bechlioulis, A | 1 |
| Kazakos, N | 1 |
| Calis, KA | 1 |
| Makrigiannakis, A | 1 |
| Katsouras, CS | 1 |
| Chrousos, GP | 1 |
| Tsatsoulis, A | 1 |
| Michalis, LK | 1 |
| Katsiki, N | 1 |
| Hatzitolios, AI | 1 |
| Li, XJ | 1 |
| Yu, YX | 1 |
| Liu, CQ | 1 |
| Zhang, W | 1 |
| Zhang, HJ | 1 |
| Yan, B | 1 |
| Wang, LY | 1 |
| Yang, SY | 1 |
| Zhang, SH | 1 |
| Eriksen, M | 1 |
| Pørneki, AD | 1 |
| Burns, JS | 1 |
| Gaster, M | 2 |
| Asadipooya, K | 1 |
| Kalantar-Hormozi, M | 1 |
| Nabipour, I | 1 |
| Rezvanfar, MA | 2 |
| Ahmadi, A | 1 |
| Saadi, HA | 1 |
| Baeeri, M | 1 |
| Abdollahi, M | 1 |
| Vinaixa, M | 1 |
| Rodriguez, MA | 1 |
| Samino, S | 1 |
| Beltran, A | 1 |
| Mallol, R | 1 |
| Bladé, C | 1 |
| Correig, X | 1 |
| Yanes, O | 1 |
| Ziaee, A | 1 |
| Oveisi, S | 1 |
| Abedini, A | 1 |
| Hashemipour, S | 1 |
| Karimzadeh, T | 1 |
| Ghorbani, A | 1 |
| Du, Q | 2 |
| Wang, YJ | 2 |
| Yang, S | 2 |
| Wu, B | 2 |
| Han, P | 1 |
| Zhao, YY | 2 |
| Fan, B | 1 |
| Kashani, L | 1 |
| Omidvar, T | 1 |
| Farazmand, B | 1 |
| Modabbernia, A | 1 |
| Ramzanzadeh, F | 1 |
| Tehraninejad, ES | 1 |
| Ashrafi, M | 1 |
| Tabrizi, M | 1 |
| Akhondzadeh, S | 1 |
| Vigerust, NF | 1 |
| Bohov, P | 1 |
| Bjørndal, B | 1 |
| Seifert, R | 1 |
| Nygård, O | 1 |
| Svardal, A | 1 |
| Berge, RK | 1 |
| Romualdi, D | 3 |
| Guido, M | 3 |
| Ciampelli, M | 1 |
| Giuliani, M | 3 |
| Leoni, F | 1 |
| Perri, C | 1 |
| Lanzone, A | 3 |
| Glueck, CJ | 1 |
| Moreira, A | 1 |
| Goldenberg, N | 2 |
| Sieve, L | 1 |
| Wang, P | 1 |
| Lord, JM | 1 |
| Flight, IH | 1 |
| Coffler, MS | 2 |
| Patel, K | 1 |
| Dahan, MH | 2 |
| Yoo, RY | 2 |
| Malcom, PJ | 2 |
| Tauchert, S | 1 |
| Schröder, AK | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Suriano, R | 1 |
| Costantini, B | 2 |
| Apa, R | 1 |
| Brettenthaler, N | 1 |
| Huber, PR | 1 |
| Keller, U | 1 |
| Ortega-González, C | 2 |
| Luna, S | 1 |
| Hernández, L | 1 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 2 |
| Parra, A | 2 |
| Cardoza, L | 1 |
| Coutiño, B | 1 |
| Hidalgo, R | 1 |
| Mehta, RV | 1 |
| Patel, KS | 1 |
| Archer, JS | 1 |
| Stout, DL | 1 |
| Fugate, SE | 1 |
| Støving, RK | 1 |
| Hagen, C | 5 |
| Hermann, AP | 5 |
| Frystyk, J | 3 |
| Veldhuis, JD | 2 |
| Flyvbjerg, A | 3 |
| Garmes, HM | 1 |
| Tambascia, MA | 1 |
| Zantut-Wittmann, DE | 1 |
| Misugi, T | 1 |
| Ozaki, K | 1 |
| El Beltagy, K | 1 |
| Tokuyama, O | 1 |
| Honda, K | 1 |
| Ishiko, O | 1 |
| Henriksen, JE | 3 |
| Berria, R | 1 |
| Gastaldelli, A | 1 |
| Lucidi, S | 1 |
| Belfort, R | 1 |
| De Filippis, E | 1 |
| Easton, C | 1 |
| Brytzki, R | 1 |
| Cusi, K | 1 |
| Jovanovic, L | 1 |
| DeFronzo, R | 1 |
| Draisci, G | 1 |
| Cristello, F | 1 |
| Andersen, KK | 1 |
| Koo, YA | 1 |
| Shin, SY | 1 |
| Yoon, BK | 1 |
| Choi, D | 1 |
| Birk, JB | 1 |
| Treebak, JT | 1 |
| Frøsig, C | 1 |
| Handberg, A | 1 |
| Wild, RA | 1 |
| Glueck, C | 1 |
| Heickendorff, L | 1 |
| Jensen, LT | 1 |
| Bennett, P | 1 |
| Ota, H | 1 |
| Goto, T | 1 |
| Yoshioka, T | 1 |
| Ohyama, N | 1 |
| Peters, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome[NCT04867252] | Phase 2 | 88 participants (Actual) | Interventional | 2021-05-03 | Completed | ||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial[NCT04113889] | Phase 2 | 147 participants (Actual) | Interventional | 2019-10-15 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome[NCT01909141] | Early Phase 1 | 100 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| The Effect of PPARgamma Stimulation on Glucose Metabolism, Insulin Resistance, Growth Hormone and Cortisol on Women Suffering From Polycystic Ovary Syndrome[NCT00145340] | Phase 4 | 30 participants | Interventional | 2002-09-30 | Completed | ||
| Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome[NCT02633488] | 19 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer[NCT03086005] | Phase 3 | 24 participants (Actual) | Interventional | 2011-10-12 | Completed | ||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Theca Cell Function in Women With Polycystic Ovary Syndrome[NCT00747617] | Phase 3 | 25 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| The Experience of Living With Polycystic Ovary Syndrome in the Military[NCT03876665] | 24 participants (Actual) | Observational | 2019-08-15 | Completed | |||
| A Multicenter Randomized Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth for Infertility in Women With Polycystic Ovary Syndrome[NCT03625531] | Phase 3 | 1,100 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01909141)
Timeframe: 3 months
| Intervention | mm (Mean) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 10.56 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 9.68 |
(NCT01909141)
Timeframe: 3 months
| Intervention | follicles (Mean) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 1.44 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 1.5 |
(NCT01909141)
Timeframe: 3 months
| Intervention | percentage of all cycles (Number) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 93 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 108 |
(NCT01909141)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 28 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 24 |
serum creatinine was measured at the end of the study period (after 3 months) in both groups. (NCT01909141)
Timeframe: 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 0.62 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 0.57 |
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature (NCT02633488)
Timeframe: before and after 12 weeks on placebo or metformin
| Intervention | percentage of artery dilation (Mean) |
|---|---|
| Pre and Post Placebo 12 Weeks | 6.1 |
| Pre and Post Metformin 12 Weeks | 6.2 |
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
Mean serum testosterone levels before and after hCG injection. Serum testosterone levels before (-0.5 and 0 hrs) were averaged to achieve a single value (NCT00747617)
Timeframe: -0.5, 0, 24 hrs
| Intervention | ng/ml (Mean) |
|---|---|
| PCOS | 0.6 |
| Normal | 0.3 |
Assess serum 17OHP levels following each dose of hCG adminstration in PCOS and normal subjects (NCT00747617)
Timeframe: 24 hrs post dose
| Intervention | ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| 17OHP post 10 micrograms | 17OHP level post 1 micrograms | 17OHP level post 25 micrograms | 17OHP level post 100 micrograms | 17OHP level post 250 micrograms | |
| Normal | 1.2 | 1.0 | 1.7 | 2.2 | 2.1 |
| PCOS | 2.0 | 1.1 | 2.7 | 3.3 | 4.0 |
17 reviews available for pioglitazone and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Insulin; Insulin Resistance; Metform | 2022 |
Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Body Weight; Female; Humans; Hypoglycemic Agents; Metformin; Orlistat; Pioglitazone; Polyc | 2022 |
The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.
Topics: Abortion, Spontaneous; Clomiphene; Female; Humans; Infertility, Female; Live Birth; Metformin; Netwo | 2023 |
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Piogl | 2017 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Piogl | 2017 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Piogl | 2017 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Piogl | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Diet; Drug Therapy, Combination; Exercise; F | 2015 |
Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Topics: Androgens; Animals; Death Domain Receptor Signaling Adaptor Proteins; Decanoic Acids; Disease Models | 2016 |
Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
Topics: Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic | 2010 |
Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
Topics: Dehydroepiandrosterone Sulfate; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin; Nausea; Pi | 2011 |
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf | 2012 |
Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.
Topics: Androgens; Blood Glucose; Body Weight; Female; Humans; Insulin; Insulin Resistance; Pioglitazone; Po | 2012 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction | 2003 |
Thiazolidinediones for treatment of polycystic ovary syndrome.
Topics: Adult; Chromans; Clinical Trials as Topic; Clomiphene; Contraceptives, Oral; Female; Fertility Agent | 2005 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exerci | 2007 |
Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.
Topics: Adult; Clomiphene; Diabetes, Gestational; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2008 |
Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Education, Continuing; Female; Humans; Hypoglycemic | 2001 |
47 trials available for pioglitazone and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial.
Topics: Adiponectin; Adult; Female; Follicle Stimulating Hormone; Humans; Inositol; Insulin; Luteinizing Hor | 2023 |
Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments.
Topics: Adolescent; Cyproterone Acetate; Diabetes Mellitus, Type 2; Female; Follistatin; Humans; Hypoglycemi | 2023 |
SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a mult
Topics: Adolescent; Carotid Intima-Media Thickness; Clinical Trials, Phase II as Topic; Female; Humans; Insu | 2023 |
Treatment with Metformin and Combination of Metformin Plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
Topics: Adult; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents | 2019 |
Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments.
Topics: Adolescent; Biomarkers; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemi | 2020 |
Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study.
Topics: Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Leptin; Metformin; Pioglitazone; | 2020 |
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity.
Topics: Adult; Animals; Cell Line; Clusterin; Disease Models, Animal; Female; Glucose; Glucose Clamp Techniq | 2020 |
Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study.
Topics: Adult; Anxiety; Comorbidity; Depression; Female; Humans; Inflammasomes; Metformin; NLR Family, Pyrin | 2020 |
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 1 | 2021 |
Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Ovulation Induction; Piog | 2021 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2017 |
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-C | 2017 |
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F | 2017 |
Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials.
Topics: Adolescent; Adult; Biomarkers; Body Mass Index; Contraceptives, Oral; Drug Therapy, Combination; Fem | 2019 |
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Topics: Adult; Biomarkers; Chemokines; Cytokines; Drug Therapy, Combination; Female; Glucose Clamp Technique | 2013 |
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
Topics: Adiponectin; Adolescent; C-Reactive Protein; Female; Fibrinogen; Hirsutism; Humans; Hyperandrogenism | 2014 |
A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Egypt; Female; F | 2016 |
Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
Topics: Adult; Biopsy; Double-Blind Method; Female; Glucose; Glycogen; Glycogen Synthase; Humans; Hypoglycem | 2008 |
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2009 |
Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.
Topics: Adult; Blood Glucose; Female; Glucose Intolerance; Glucose Tolerance Test; Gonadal Steroid Hormones; | 2009 |
Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.
Topics: Adipokines; Adult; Area Under Curve; Blood Glucose; Double-Blind Method; Female; Hirsutism; Humans; | 2009 |
Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment.
Topics: Adiposity; Chemokine CCL2; Chemokine CCL3; Cholesterol; Female; Humans; Hypoglycemic Agents; Intramo | 2009 |
Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome.
Topics: Adult; Female; Fertilization in Vitro; Follow-Up Studies; Humans; Ovary; Ovulation Induction; Piogli | 2010 |
Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Menstr | 2009 |
Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.
Topics: Adolescent; Alanine Transaminase; Androgens; Androstenes; Aspartate Aminotransferases; Blood Glucose | 2010 |
Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.
Topics: Adolescent; Adult; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Female; Humans; | 2011 |
Pioglitazone reduces central obesity in polycystic ovary syndrome women.
Topics: Adult; Body Mass Index; Body Weight; Female; Hirsutism; Humans; Hypoglycemic Agents; Intra-Abdominal | 2012 |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.
Topics: Abdominal Fat; Biomarkers; Carotid Intima-Media Thickness; Chromatography, Gas; Chromatography, Liqu | 2011 |
Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Female | 2012 |
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.
Topics: Adolescent; Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Double-Blind Metho | 2013 |
Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment.
Topics: Adult; Carnitine; Female; Humans; Hypoglycemic Agents; Obesity; Pioglitazone; Polycystic Ovary Syndr | 2012 |
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Acne Vulgaris; Adolescent; Adult; Androgens; Androstenedione; Body Con | 2003 |
Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone.
Topics: Adult; Case-Control Studies; Dose-Response Relationship, Drug; Estradiol; Female; Follicle Stimulati | 2003 |
[The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome].
Topics: Acarbose; Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Met | 2003 |
Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgens; Androst | 2004 |
Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
Topics: Adult; Double-Blind Method; Female; Glucose Intolerance; Hormones; Humans; Hyperandrogenism; Insulin | 2004 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2005 |
Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.
Topics: Absorptiometry, Photon; Adult; Area Under Curve; Body Composition; Cholinesterase Inhibitors; Double | 2005 |
Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Double-Blind Method; Fasting; Female; Glucose Clamp Technique; Hormones; Human | 2006 |
Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgens; Corticotropin-Releasing H | 2007 |
Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome.
Topics: Adiponectin; Blood Glucose; Fasting; Female; Glucose Clamp Technique; Humans; Lipid Metabolism; Piog | 2008 |
Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.
Topics: Antigens, CD; Atherosclerosis; Biomarkers; Blood Glucose; Body Composition; C-Reactive Protein; Dipe | 2008 |
Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial.
Topics: Adult; Alkaline Phosphatase; Body Composition; Bone Density; Female; Gonadal Steroid Hormones; Human | 2008 |
A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adiponectin; Androsterone; Blood Glucose; Denmark; Etiocholan | 2009 |
Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome.
Topics: Adult; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Female; Pioglitaz | 2008 |
26 other studies available for pioglitazone and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis.
Topics: Computational Biology; Databases, Protein; Drug Repositioning; Female; Gene Expression Regulation; H | 2021 |
Does Pten have an impact on oogenesis of PCOS mouse models?
Topics: Animals; Clomiphene; Female; Metformin; Mice; Oogenesis; Ovulation Induction; Phosphatidylinositol 3 | 2023 |
Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions.
Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlle | 2023 |
Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α.
Topics: Animals; Female; Hepatocyte Nuclear Factors; Humans; Insulin; Insulin Resistance; Lipid Metabolism; | 2023 |
Interaction between OCT1 and LPIN1 polymorphisms and response to pioglitazone-metformin tablets in patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Phosphatidate Phosphatase; Piogl | 2023 |
Beneficial effects of pioglitazone and α-lipoic acid in patients with polycystic ovaries syndrome.
Topics: Animals; Body Weight; Female; Humans; Insulin; Mice; Pioglitazone; Polycystic Ovary Syndrome; Thioct | 2023 |
Polycystic ovary syndrome in adolescent girls.
Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone | 2020 |
Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments.
Topics: Adolescent; Female; Gastrointestinal Microbiome; Humans; Metformin; Pioglitazone; Polycystic Ovary S | 2021 |
Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance.
Topics: Animals; Animals, Genetically Modified; Body Weight; Disease Models, Animal; Female; Hypoglycemic Ag | 2018 |
Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats.
Topics: Animals; Body Weight; Carboxymethylcellulose Sodium; Diet, High-Fat; Female; Glucose Tolerance Test; | 2018 |
Trends, in Diagnosis and Treatment of Polycystic Ovarian Syndrome by Specialty.
Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Diagnostic Tests, Routine; Diuretics; Endocrinolo | 2016 |
Beneficial effects of pioglitazone and metformin in murine model of polycystic ovaries via improvement of chemerin gene up-regulation.
Topics: Adipokines; Animals; Chemokines; Disease Models, Animal; Drug Combinations; Drug Resistance; Female; | 2014 |
Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cholesterol | 2014 |
Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome.
Topics: Adiponectin; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mitoch | 2008 |
Conduct disorder in an adolescent girl treated with an insulin-sensitizing agent.
Topics: Adolescent; Cabergoline; Conduct Disorder; Dopamine Agonists; Drug Therapy, Combination; Ergolines; | 2008 |
Insulin resistance is not conserved in myotubes established from women with PCOS.
Topics: Adult; Cell Differentiation; Female; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agent | 2010 |
Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: biochemical and pathological evidences for beneficial effect of pioglitazone.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aromatase Inhibitors; Estradiol; Female; Hypoglycem | 2012 |
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
Topics: Adolescent; Adult; Diet, Reducing; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; M | 2003 |
Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment.
Topics: Adult; Androstenedione; Female; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic Agents; Insulin | 2005 |
Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Hormone Antagonists; Humans; Hyperandrogenism; Hyperinsulinism; Obesity; | 2005 |
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats.
Topics: 17-Hydroxysteroid Dehydrogenases; Adjuvants, Immunologic; Animals; Chromans; Dehydroepiandrosterone; | 2006 |
Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Body Composition; Body Mass Index; Body Weight; Female; Glucose Tolerance Test; He | 2006 |
Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol; Enzyme | 2007 |
Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
Topics: Adult; Blood Glucose; Enzyme Activation; Female; Glucose Clamp Technique; GTPase-Activating Proteins | 2008 |
Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint.
Topics: Adult; Atherosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipidemias; Metfor | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |